Correlation Between NeuroSense Therapeutics and Acrivon Therapeutics,

Can any of the company-specific risk be diversified away by investing in both NeuroSense Therapeutics and Acrivon Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining NeuroSense Therapeutics and Acrivon Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between NeuroSense Therapeutics Ltd and Acrivon Therapeutics, Common, you can compare the effects of market volatilities on NeuroSense Therapeutics and Acrivon Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in NeuroSense Therapeutics with a short position of Acrivon Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of NeuroSense Therapeutics and Acrivon Therapeutics,.

Diversification Opportunities for NeuroSense Therapeutics and Acrivon Therapeutics,

-0.25

Correlation Coefficient

NeuroSense Therapeutics  Acrivon Therapeutics,

Very good diversification

The 3 months correlation between NeuroSense and Acrivon is -0.25. Overlapping area represents the amount of risk that can be diversified away by holding NeuroSense Therapeutics Ltd and Acrivon Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Acrivon Therapeutics, and NeuroSense Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on NeuroSense Therapeutics Ltd are associated (or correlated) with Acrivon Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Acrivon Therapeutics, has no effect on the direction of NeuroSense Therapeutics i.e., NeuroSense Therapeutics and Acrivon Therapeutics, go up and down completely randomly.

Pair Corralation between NeuroSense Therapeutics and Acrivon Therapeutics,

Assuming the 90 days horizon NeuroSense Therapeutics Ltd is expected to generate 8.8 times more return on investment than Acrivon Therapeutics,. However, NeuroSense Therapeutics is 8.8 times more volatile than Acrivon Therapeutics, Common. It trades about 0.2 of its potential returns per unit of risk. Acrivon Therapeutics, Common is currently generating about -0.04 per unit of risk. If you would invest  16.00  in NeuroSense Therapeutics Ltd on September 16, 2024 and sell it today you would earn a total of  9.00  from holding NeuroSense Therapeutics Ltd or generate 56.25% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	52.31%
Values	Daily Returns

NeuroSense Therapeutics Ltd  vs.  Acrivon Therapeutics, Common

NeuroSense Therapeutics

Risk-Adjusted Performance

15 of 100

Good

Compared to the overall equity markets, risk-adjusted returns on investments in NeuroSense Therapeutics Ltd are ranked lower than 15 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, NeuroSense Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Acrivon Therapeutics,

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Acrivon Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest unsteady performance, the Stock's basic indicators remain stable and the latest fuss on Wall Street may also be a sign of long-term gains for the venture sophisticated investors.

Pair Trading with NeuroSense Therapeutics and Acrivon Therapeutics,

The main advantage of trading using opposite NeuroSense Therapeutics and Acrivon Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if NeuroSense Therapeutics position performs unexpectedly, Acrivon Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acrivon Therapeutics, will offset losses from the drop in Acrivon Therapeutics,'s long position.

The idea behind NeuroSense Therapeutics Ltd and Acrivon Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.